

Evidence dossier - OrbiMed Advisors

GetCoattail manager profile: <https://getcoattail.com/manager/orbimed-advisors> | CIK 0001055951 | Rank #94 of 149 tracked managers by reported 13F value.

Background: Founded: 1989 | HQ: New York, New York, U.S. | Style: Healthcare-dedicated investing across public equity, private equity and royalty/credit | Key person: Sam Isaly

Background source: <https://www.insidermonkey.com/hedge-fund/orbimed+advisors/254>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: \$5.4B Positions: 129 Top-10 concentration: 42.1% of reported value.

Ticker	Company	Weight	Reported value
EWTX	Edgewise Therapeutics Inc	11.68%	\$631M
ELVN	Enliven Therapeutics Inc	6.37%	\$344M
LLY	Eli Lilly & Co	5.73%	\$309M
MBX	Mbx Biosciences Inc	3.51%	\$189M
SVA	Sinovac Biotech Ltd	3.42%	\$184M
AZN	Astrazeneca Plc	3.17%	\$171M
GPCR	Structure Therapeutics Inc	2.20%	\$119M
SION	Sionna Therapeutics Inc	2.08%	\$112M
CRVS	Corvus Pharmaceuticals Inc	1.98%	\$107M
AVBP	Arrivent Biopharma Inc	1.95%	\$105M

2. Hypothetical 13F-clone results

Window: 2016-11-14 to 2026-10-02 (40 filings). Cumulative: +71.8% CAGR: +5.63% SPY same window: cumulative +316.1%, CAGR +15.52%. Trailing CAGR - 10Y: n/a, 5Y: +1.00%, 3Y: +13.61%, 1Y: +11.84%. Max drawdown (month-end, approximate): -48.2%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001172661-16-004318	2016-11-14	125
2016Q4	0001172661-17-000766	2017-02-14	118
2017Q1	0001172661-17-001216	2017-05-15	124
2017Q2	0001172661-17-001699	2017-08-14	125
2017Q3	0001172661-17-002146	2017-11-14	129
2017Q4	0001172661-18-000795	2018-02-14	123
2018Q1	0001172661-18-001239	2018-05-15	124

2018Q2	0001172661-18-001660	2018-08-14	134
2018Q3	0001172661-18-002168	2018-11-14	140
2018Q4	0001172661-19-000868	2019-02-14	123
2019Q1	0001172661-19-001382	2019-05-15	116
2019Q2	0001172661-19-001883	2019-08-14	119
2019Q3	0001172661-19-002352	2019-11-14	108
2019Q4	0001172661-20-000859	2020-02-14	132
2020Q1	0001172661-20-001407	2020-05-15	138
2020Q2	0001172661-20-001859	2020-08-14	131
2020Q3	0001172661-20-002295	2020-11-16	140
2020Q4	0001172661-21-000786	2021-02-16	146
2021Q1	0001172661-21-001345	2021-05-17	152
2021Q2	0001172661-21-001841	2021-08-16	153
2021Q3	0001172661-21-002332	2021-11-15	166
2021Q4	0001172661-22-000795	2022-02-14	155
2022Q1	0001172661-22-001456	2022-05-16	137
2022Q2	0001172661-22-001998	2022-08-15	134
2022Q3	0001172661-22-002553	2022-11-14	126
2022Q4	0001172661-23-001310	2023-02-14	112
2023Q1	0001172661-23-002323	2023-05-15	114
2023Q2	0001172661-23-003177	2023-08-14	118
2023Q3	0001172661-23-004019	2023-11-14	120
2023Q4	0001172661-24-001461	2024-02-14	109
2024Q1	0001172661-24-002506	2024-05-15	112
2024Q2	0001172661-24-003539	2024-08-14	108
2024Q3	0001172661-24-005167	2024-11-14	109
2024Q4	0001172661-25-001136	2025-02-14	111
2025Q1	0001172661-25-002355	2025-05-15	106
2025Q2	0001172661-25-003514	2025-08-14	97
2025Q3	0001172661-25-005047	2025-11-14	98
2025Q4	0001172661-26-001119	2026-02-17	104
2026Q1	0001172661-26-002369	2026-05-15	105
2026Q2	0001172661-26-003740	2026-08-14	117

4. Coverage and adjustments

Price coverage at the latest filing: 73.8% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.